Single-agent expansion cohort of lenvatinib (LEN) and combination dose-finding cohort of LEN + etoposide (ETP) + ifosfamide (IFM) in patients (pts) aged 2 to ≤25 years with relapsed/refractory osteosarcoma (OS)

Authors :: Corina E. Dutcus
Michela Casanova
Quentin Campbell-Hewson
Claudia Rossig
Silvija Kraljevic
Adela Cañete
Soledad Gallego Melcon
Sandra J. Strauss
Isabelle Aerts
Bruce Morland
Seiichi Hayato
Marion Gambart
Francisco José Bautista Sirvent
Nathalie Gaspar
Stefan S. Bielack
Cixin He
Perrine Marec-Berard
Estelle Thebaud
Franco Locatelli
Rajkumar Venkatramani
Source :: Journal of Clinical Oncology. 36:11527-11527
Publication Year :: 2018
Publisher :: American Society of Clinical Oncology (ASCO), 2018.
Abstract: 11527Background: LEN is a multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET. In human pediatric OS xenograft models, LEN enhanced the antitumor activity of IFM + ETP. In a phase (Ph)...

Tools